Literature DB >> 20825431

Molecular analysis of Sanfilippo syndrome type C in Spain: seven novel HGSNAT mutations and characterization of the mutant alleles.

I Canals1, S C Elalaoui, M Pineda, V Delgadillo, M Szlago, I C Jaouad, A Sefiani, A Chabás, M J Coll, D Grinberg, L Vilageliu.   

Abstract

The Sanfilippo syndrome type C [mucopolysaccharidosis IIIC (MPS IIIC)] is caused by mutations in the HGSNAT gene, encoding an enzyme involved in heparan sulphate degradation. We report the first molecular study on several Spanish Sanfilippo syndrome type C patients. Seven Spanish patients, one Argentinean and three Moroccan patients were analysed. All mutant alleles were identified and comprised nine distinct mutant alleles, seven of which were novel, including four missense mutations (p.A54V, p.L113P, p.G424V and p.L445P) and three splicing mutations due to two point mutations (c.633+1G>A and c.1378-1G>A) and an intronic deletion (c.821-31_821-13del). Furthermore, we found a new single nucleotide polymorphism (SNP) (c.564-98T>C). The two most frequent changes were the previously described c.372-2A>G and c.234+1G>A mutations. All five splicing mutations were experimentally confirmed by studies at the RNA level, and a minigene experiment was carried out in one case for which no fibroblasts were available. Expression assays allowed us to show the pathogenic effect of the four novel missense mutations and to confirm that the already known c.710C>A (p.P237Q) is a non-pathogenic SNP. Haplotype analyses suggested that the two mutations (c.234+1G>A and c.372-2A>G) that were present in more than one patient have a common origin, including one (c.234+1G>A) that was found in Spanish and Moroccan patients.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20825431     DOI: 10.1111/j.1399-0004.2010.01525.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  9 in total

1.  Update of the spectrum of mucopolysaccharidoses type III in Tunisia: identification of three novel mutations and in silico structural analysis of the missense mutations.

Authors:  Souad Ouesleti; Maria Francisca Coutinho; Isaura Ribeiro; Abdehedi Miled; Dalila Saidane Mosbahi; Sandra Alves
Journal:  World J Pediatr       Date:  2017-01-19       Impact factor: 2.764

2.  Natural History and Molecular Characteristics of Korean Patients with Mucopolysaccharidosis Type III.

Authors:  Min-Sun Kim; Aram Yang; Eu-Seon Noh; Chiwoo Kim; Ga Young Bae; Han Hyuk Lim; Hyung-Doo Park; Sung Yoon Cho; Dong-Kyu Jin
Journal:  J Pers Med       Date:  2022-04-21

3.  Characterization of the biosynthesis, processing and kinetic mechanism of action of the enzyme deficient in mucopolysaccharidosis IIIC.

Authors:  Xiaolian Fan; Ilona Tkachyova; Ankit Sinha; Brigitte Rigat; Don Mahuran
Journal:  PLoS One       Date:  2011-09-21       Impact factor: 3.240

4.  Natural history of Sanfilippo syndrome in Spain.

Authors:  Verónica Delgadillo; Maria del Mar O'Callaghan; Laura Gort; Maria Josep Coll; Mercedes Pineda
Journal:  Orphanet J Rare Dis       Date:  2013-12-06       Impact factor: 4.123

5.  Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations.

Authors:  Liliana Matos; Isaac Canals; Larbi Dridi; Yoo Choi; Maria João Prata; Peter Jordan; Lourdes R Desviat; Belén Pérez; Alexey V Pshezhetsky; Daniel Grinberg; Sandra Alves; Lluïsa Vilageliu
Journal:  Orphanet J Rare Dis       Date:  2014-12-10       Impact factor: 4.123

6.  Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC.

Authors:  Sara Marcó; Anna Pujol; Carles Roca; Sandra Motas; Albert Ribera; Miguel Garcia; Maria Molas; Pilar Villacampa; Cristian S Melia; Víctor Sánchez; Xavier Sánchez; Joan Bertolin; Jesús Ruberte; Virginia Haurigot; Fatima Bosch
Journal:  Dis Model Mech       Date:  2016-08-04       Impact factor: 5.758

7.  The first Korean case of mucopolysaccharidosis IIIC (Sanfilippo syndrome type C) confirmed by biochemical and molecular investigation.

Authors:  Hee Jae Huh; Ja Young Seo; Sung Yoon Cho; Chang-Seok Ki; Soo-Youn Lee; Jong-Won Kim; Hyung-Doo Park; Dong-Kyu Jin
Journal:  Ann Lab Med       Date:  2012-12-17       Impact factor: 3.464

8.  EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for Sanfilippo C syndrome.

Authors:  Isaac Canals; Noelia Benetó; Mónica Cozar; Lluïsa Vilageliu; Daniel Grinberg
Journal:  Sci Rep       Date:  2015-09-08       Impact factor: 4.379

9.  Activity and High-Order Effective Connectivity Alterations in Sanfilippo C Patient-Specific Neuronal Networks.

Authors:  Isaac Canals; Jordi Soriano; Javier G Orlandi; Roger Torrent; Yvonne Richaud-Patin; Senda Jiménez-Delgado; Simone Merlin; Antonia Follenzi; Antonella Consiglio; Lluïsa Vilageliu; Daniel Grinberg; Angel Raya
Journal:  Stem Cell Reports       Date:  2015-09-24       Impact factor: 7.765

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.